Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
Identification and evaluation of Pharmacological enhancers of the factor VII p.Q160R variant
by
Stavik, B.
, Andresen, M. S.
, Chollet, M. E.
, Sandset, P. M.
, Andersen, E.
, Mowinckel, M. C.
, Skarpen, E.
in
631/154
/ 631/337
/ 631/80
/ 692/4017
/ Drug repurposing
/ Factor VII - genetics
/ Factor VII - metabolism
/ Factor VII Deficiency - drug therapy
/ Factor VII Deficiency - genetics
/ FVII deficiency
/ High-throughput screening
/ Histone Deacetylase Inhibitors - pharmacology
/ Humanities and Social Sciences
/ Humans
/ Intracellular transport
/ multidisciplinary
/ Mutation
/ Science
/ Science (multidisciplinary)
2025
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Identification and evaluation of Pharmacological enhancers of the factor VII p.Q160R variant
by
Stavik, B.
, Andresen, M. S.
, Chollet, M. E.
, Sandset, P. M.
, Andersen, E.
, Mowinckel, M. C.
, Skarpen, E.
in
631/154
/ 631/337
/ 631/80
/ 692/4017
/ Drug repurposing
/ Factor VII - genetics
/ Factor VII - metabolism
/ Factor VII Deficiency - drug therapy
/ Factor VII Deficiency - genetics
/ FVII deficiency
/ High-throughput screening
/ Histone Deacetylase Inhibitors - pharmacology
/ Humanities and Social Sciences
/ Humans
/ Intracellular transport
/ multidisciplinary
/ Mutation
/ Science
/ Science (multidisciplinary)
2025
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Identification and evaluation of Pharmacological enhancers of the factor VII p.Q160R variant
by
Stavik, B.
, Andresen, M. S.
, Chollet, M. E.
, Sandset, P. M.
, Andersen, E.
, Mowinckel, M. C.
, Skarpen, E.
in
631/154
/ 631/337
/ 631/80
/ 692/4017
/ Drug repurposing
/ Factor VII - genetics
/ Factor VII - metabolism
/ Factor VII Deficiency - drug therapy
/ Factor VII Deficiency - genetics
/ FVII deficiency
/ High-throughput screening
/ Histone Deacetylase Inhibitors - pharmacology
/ Humanities and Social Sciences
/ Humans
/ Intracellular transport
/ multidisciplinary
/ Mutation
/ Science
/ Science (multidisciplinary)
2025
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Identification and evaluation of Pharmacological enhancers of the factor VII p.Q160R variant
Journal Article
Identification and evaluation of Pharmacological enhancers of the factor VII p.Q160R variant
2025
Request Book From Autostore
and Choose the Collection Method
Overview
Congenital factor (F) VII deficiency is caused by mutations in the
F7
gene. The p.Q160R variant manifests with bleeding episodes due to reduced FVII activity and antigen in patient plasma, most likely caused by protein misfolding and intracellular retention. As current replacement therapy is expensive and requires frequent intravenous injections, there is an unmet need for new and less invasive therapeutic strategies. Drug repurposing allows for rapid, more cost-effective discovery and implementation of new treatments, and identification of pharmacological enhancers of FVII variant activity would be of clinical importance. High-throughput screening of > 1800 FDA-approved drugs identified the orally available histone deacetylase inhibitor abexinostat and the inhaled surfactant tyloxapol as enhancers of FVII p.Q160R variant activity. The positive hits were verified in an in vitro cell model transiently expressing wild type or variant FVII and ex vivo in patients’ plasma. Both drugs showed a dose-response effect on FVII antigen and activity levels in conditioned cell medium and on FVII activity in patients’ plasma. In conclusion, the efficacy of the FDA-approved drugs abexinostat and tyloxapol in enhancing FVII variant activity constitute a proof of principle for high-throughput identification of drugs that may be feasible for novel treatment of FVII deficiency.
Publisher
Nature Publishing Group UK,Nature Portfolio
This website uses cookies to ensure you get the best experience on our website.